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Background: The aim of our study was to evaluate factors affecting cystic fibrosis (CF) patients’ health-related
quality of life (HRQoL) and to assess the level of agreement on HRQol between children and their parents.
Methods: Fifty-nine patients (mean age: 14.03 ± 4.81 years) from 5 Hungarian CF centres completed the survey.
HRQoL was measured using The Cystic Fibrosis Questionnaire-Revised (CFQ-R). Parents were asked to fill out a
questionnaire about their smoking habits, educational level and history of chronic illness. Disease severity was
assessed using the physician-reported Shwachman-Kulczycki (SK) score system. Spirometry, Body Mass Index (BMI)
percentile (pc), hospitalisation and Pseudomonas aeruginosa (PA) infection were examined as physiologic parameters
of CF, and the impact of these factors on HRQoL was assessed. A multivariate regression analysis was performed to
identify the most important factors affecting HRQoL. The level of significance was set to 0.05.
Results: Passive smoking and parental educational level and chronic diseases status did not have a significant
impact on the patients’ HRQoL (p > 0.05). Significantly lower SK scores and spirometry values were found in low
BMI pc patients (p < 0.001), in hospitalised (p < 0.01) and in PA-infected patients (p < 0.01), than in the adequate-
weight, non-hospitalised and PA culture-negative subgroup. Lower CFQ-R scores were detected in hospitalised
patients than in non-hospitalised patients in their Physical functioning domain. PA-infected patients had HRQoL
scores that were significantly worse in the Body image (p < 0.01) and Respiratory symptoms (p < 0.05) domains than
the PA culture-negative patients. Patients with a low BMI pc (<25th BMI pc) had significantly lower scores in the
Eating, Body image and Treatment burden domains, than the adequate-weight patients (>25th BMI pc) (p < 0.01). A
strong child–parent agreement was found in the Physical functioning domain (r = 0.77, p < 0.01).
Conclusions: Passive smoking, parental educational level and chronic diseases of parents do not affect the HRQoL
of CF patients. In contrast, hospitalisation, PA infection and malnutrition have a significant and negative impact on
patients’ HRQoL and the clinical severity of the disease. Parents and children were consistent in their scoring of
symptoms and behaviours that were observable.
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Cystic fibrosis (CF) is a life-shortening, progressive multi-
system disease with a significant impact on patients’
health-related quality of life (HRQoL). It is the most com-
mon recessive disease among Caucasian populations, af-
fecting 597 patients in Hungary, of whom 436 were
between ages 8 and 30 years in 2010 [1]. The life expect-
ancy of patients with cystic fibrosis has improved in the
past decades. The therapeutic approach to the modern
treatment of chronic diseases has changed. The aim now
is not only to extend life but also to improve the quality of
life. To improve the quality of medical attendance in CF,
pulmonologists, gastroenterologists, CF nurses, dieticians,
social workers and respiratory therapists work in collabor-
ation as members of CF healthcare teams.
There are still limited studies measuring HRQoL in
CF patients from Eastern Europe, although such studies
could provide valuable information about the psycho-
logical and social impact of CF treatment. The primary
aim of clinical trials is to evaluate the effectiveness of
treatments based on clinical variables; HRQoL is often
viewed as a secondary endpoint [2,3]. More interdiscip-
linary work should focus on the impact of CF treatment
on the daily life and emotional development of children
with the disease [4]. Previous studies have emphasised
the importance of HRQoL evaluations in children with
chronic respiratory illnesses using both patient-reporting
and parent-proxy reporting [5-8].
There are some healthcare challenges regarding the
management of CF in Hungary. Newborn screening and
routine measurements of the level of anti-Pseudomonas
antibodies are not available during the care of CF pa-
tients in their daily management. In Eastern European
countries, such as Hungary, the diagnosis of CF is usu-
ally delayed because newborn screening is not available;
therefore, it is difficult to prevent the development of
early lung disease. Furthermore, the oral flucloxacillin
prophylaxis for infants is also unavailable in our country.
The inability to measure the level of faecal elastase
means that it is not possible to estimate pancreatic in-
sufficiency in Hungarian CF patients using objective
methods. The organisational structure of holistic CF care
also fails in Hungary. We do not have true CF teams
with physiotherapists and psychologists who are specia-
lised in treating patients with CF. These negative differ-
ences compared with Western European CF care may
decrease our patients’ life expectancy and HRQoL.
Countless factors may influence the perception of
HRQoL in CF. The impact of socioeconomic status, race
and ethnicity has been identified [9]. It is known that gen-
der and disease severity affect HRQoL in CF patients [10];
coping style related positively to HRQoL and might be
helpful during CF care [11]. The importance of achieving
optimum nutritional status has also been demonstrated[12], and it is known that normal body weight is associ-
ated with better lung function in CF patients [13]. It has
also been shown that body mass index (BMI) correlated
moderately with forced expiratory volume in 1 second
(FEV1) and forced vital capacity (FVC) in adults with CF.
Most patients with severe malnutrition are homozygous
for p.Phe508del [14]. Quittner and colleagues measured a
significant correlation between HRQoL and BMI [5]. They
also found a negative impact of Pseudomonas aeruginosa
(PA) infection on both HRQoL and lung function [15].
Increasing significance has been ascribed to patient-
reported outcome (PRO) studies in health economics.
However, in Eastern Europe, few PRO studies have been
carried out in CF patients. Our study could provide the
first comparable HRQoL data from Eastern Europe. To
clarify the nature of the relationship between child and
parent ratings and to identify the factors affecting
HRQoL in CF, our study objectives were as follows:
1. To investigate the relationships between
demographic variables, disease severity, pulmonary
variables, nutritional status and HRQoL in CF
patients.
2. To assess the level of agreement of HRQoL scores
between children/adolescents with CF and their
parents.
Methods
Study design
Our multi-centre study was based on single cross-
sectional data collection from children, adolescents and
young adults aged 8–30 years with CF in five Hungarian
CF outpatient centres between September 2010 and
October 2011.
Participants
Sixty-six CF patients were asked to participate, and 59
(89.4%) children were prospectively included in the study.
Inclusion criteria were an age between 8 and 30 years,
diagnosis of CF and the presence of a caregiver during
the measurement for patients <18 years. The age was re-
stricted to 8–30 years because in most instances, young
adults (between 18–30 years) are treated in children
centres in Hungary, while the transmission to adult care
is not consistent; furthermore, we wanted to measure
the HRQoL of both children and young adults.
Patients with clinical exacerbation, acute respiratory
infection, other chronic illnesses, mental retardation or
reading difficulties were excluded.
The study has been approved by the Semmelweis Uni-
versity Regional and Institutional Committee of Science
and Research Ethics. Written informed consent and
assent was obtained according to principles of the ethics
committee. Legal guardians of children and adolescents
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young adults over 18 years old.
Study measures
Health-related quality of life (HRQoL): The Cystic Fibro-
sis Questionnaire-Revised (CFQ-R) is a widely used, vali-
dated, disease-specific instrument for the measurement
of HRQoL in patients with CF [5,6,9,11]. The Hungarian
version of CFQ-R was used to evaluate HRQoL from
both the patient’s perspective (patient-report) and their
parent’s perspective (parent-proxy report). The CFQ-R
has both generic (Physical functioning, Social function-
ing, Emotional functioning) and disease-specific (Treat-
ment burden, Respiratory symptoms) dimensions. There
are four versions of the CFQ-R [15-17]:
 CFQ-R Child: an interviewer-administered version
with 35 items divided into 8 domains (Physical
functioning, Emotional functioning, Social functioning,
Body image, Eating, Treatment burden, Respiratory
symptoms, Digestive symptoms) that was designed for
children aged 6–11 years.
 CFQ-R Child: a patient-report version with 35 items
divided into 8 domains (the same CFQ-R domains
as for children aged 6 to 11 years) that was designed
for children aged 12–13 years.
 CFQ-R Teen/Adult: a patient-report version with 50
items divided into 12 domains (8 domains described
above with four additional domains: Role functioning,
Vitality, Weight and Health perceptions) that was
designed for patients aged ≥ 14 years.
 CFQ-R Parent: a proxy-report for the parents of
children aged 6–13 years with 44 items divided into
11 domains (Physical functioning, Emotional
functioning, Vitality, School functioning, Body
image, Eating, Treatment burden, Respiratory
symptoms, Digestive symptoms, Weight and Health
perceptions).
The questionnaire provides a summary score for each
domain; between 0 and 100, where higher scores indi-
cate a greater HRQoL. Response choices include ratings
of frequency and difficulty on a 4-point Likert scale (1 =
always to 4 = never, 1 = a lot of difficulty to 4 = no diffi-
culty) or true or false responses (1 = very true to 4 = very
false). Scoring was computed only if at least half of the
questions were completed within each domain. The do-
main scores of the CFQ-R Child and CFQ-R Teen were
combined because of a consultation with the developer
of the questionnaires. Through the combination process,
we lost 4 domains because the teen/adult version con-
tained more dimensions than the child version. The
minimal clinically important difference (MCID) for the
CFQ-R Respiratory scale was 4.0 points, which is thesmallest difference in scores that patients perceive as
clinically beneficial [15].
Data on the participants was extracted from their
medical records and included their current height,
weight, infection status with mucoid strains of PA, and
any hospitalisations during the previous year.
Lung function tests: Forced expiratory volume in 1 sec-
ond (FEV1) was measured, and expressed as the percent-
age of the predicted value based on gender, age and
height.
The Shwachman-Kulczycki (SK) score was used to cat-
egorise the patients based on their clinical health status.
The SK score is a general score of clinical severity; it is
divided into four domains, including general activity,
physical examination, nutrition and radiological findings,
which are scored between 0–25, according to the degree
of impairment. The total SK score adds up to 100. SK
scores can be excellent (86–100), good (71–85), mild
(56–70), moderate (41–55) or severe (<40) [18].
Body mass index (BMI) percentile (pc) was calculated
for patients under 18 years of age and BMI (weight [kg]/
height [m]2) was calculated for patients above 18 years
to estimate their nutritional status. The nutritional status
of children (<18 years) was defined as low if their BMI
pc value was below the 25th percentile, if their BMI pc
value was above the 25th percentile, they were instead
categorised as adequate-weight. Malnutrition was de-
fined as a BMI below 18.5 in adults, according to the
WHO report [19,20].
Young adults and parents of children were asked to fill
out a questionnaire about passive smoking and the par-
ental educational level and history of chronic illnesses.
Statistical analyses
Data are expressed as either the mean ± standard devi-
ation (SD) or frequencies (%). Pearson’s correlation coef-
ficient (r) was used to observe the strength of the
relationships. Pearson’s test was used to compare pro-
portions, and the two-tailed t-test was used to compare
means.
The significance level was defined as p ≤ 0.05. Correl-
ation coefficients (r) were defined as weak, if r < 0.3,
moderate if r = 0.3-0.7 and strong if r > 0.7 [21].
Pearson’s Chi-Square test for categorical variables and
the Mann–Whitney U test for continuous variables were
used to calculate significant differences in subgroups in
terms of their BMI pc (low BMI pc, adequate-weight),
hospitalisation history (Yes, No), current PA infection
(PA-infected, Not-infected), passive smoking (Yes, No)
and parental educational level (primary, secondary, higher
education). After the assessment of simple correlations be-
tween the demographic variables, SK score, physiologic
parameters and CFQ-R scales, we performed a multivari-
ate regression analysis according to a stepwise model to
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domains.
Statistical analyses were performed using Statistical
Package for the Social Sciences for Windows version
15.0 (SPSS 15.0).
Results
Demographic characteristics
A total of 66 patients with CF consented to join the
study. One caregiver withdrew a child from participa-
tion. Two patients were excluded due to acute respira-
tory infection and one was excluded due to mental
retardation. Three patients, were excluded because of a
questionable diagnosis given their lack of any detected
genetic mutations and a positive sweat test (conductivity
> 90 mEq/l by pilocarpine iontophoresis). The final sam-
ple consisted 59 participants.
If patients were older than 14 years, parents did not
complete the CFQ-R Parent version. A ten-year-old boy
did not complete the CFQ-R Child questionnaire, but
his parent filled out the CFQ-R Parent version, resulting
in a total of 58 CFQ-R questionnaires by patient-report.
The clinical status of twelve patients (20.3%) was ex-
cellent, of thirty-three (55.9%) patients was good, of
eight (13.6%) patients was mild, of four (6.8%) patients
was moderate and of two (3.4%) patients was severe ac-
cording to their SK scores. The demographic and clinical
data of the patients are summarised in Table 1.
Association between demographic variables and HRQoL
Level of correlations is represented in Table 2.
Passive smoking, parents’ educational level (r takes
values between r = [−0.11-(+0.28)], p > 0.05) and theTable 1 Patient demographics and baseline characteristics
(n = 59)
Characteristics N % M SD
Age in years 59 14.03 (8.0-30.0) 4.81
Gender, male 28 47.5
±Ethnicity, Caucasian 54 93.1
Homozygous p.Phe508del 30 50.8
*BMI percentile <25 pc 22 37.0
BMI kg/m2 14 20.42 (16.5-25.1) 2.44
FEV1, % predicted 59 77.93 (24.0-122.0) 23.72
Shwachman-Kulczycki score 59 77.97 (35.0-100.0) 13.71
Pseudomonas aeruginosa
positive at time of study
33 55.9
Hospitalisation in the
last 12 months
Yes 17 32.1
BMI = Body Mass Index, FEV1 = Forced Expiratory Volume in 1 second.
±Data available: n = 58, for ethnicity status.
*Under 18 years of age. Data available: n = 44 for BMI percentile.chronic diseases status of the parents [r = −0.17-(+0.23),
p > 0.05] had no significant impact on the children’s
HRQoL according to patient-report. The relationship be-
tween the CFQ-R scores of the proxy-reports was not sig-
nificantly influenced by the parental educational levels [r
is within a range of r = −0.29-(+0.32), p > 0.05] or the pres-
ence of chronic illness in the caregiver [r = −0.27-(+0.33),
p > 0.05].
Association between disease severity, pulmonary
variables, clinical parameters and HRQoL
Disease severity was evaluated using a physician-reported
score system, the SK score.
As a result of the multivariate regression analysis a mod-
erate relationship was measured between the SK score
and the following CFQ-R domains: Physical functioning
(r = 0.55, R2 = 0.35, p < 0.01), Body image (r = 0.41, R2 =
0.28 for SK and PA, p < 0.01) and Respiratory symptoms
scores (r = 0.43, p < 0.01), as assessed by patient-report.
In the case of parent-proxy reports, a moderate correl-
ation was found between the SK score and the following
CFQ-R domains: Physical functioning (r = 0.67, p < 0.01),
Treatment burden (r = 0.39, p < 0.05), Health perceptions
(r = 0.43, p < 0.05), Weight (r = 0.59, p < 0.01) and Re-
spiratory symptoms (r = 0.60, p < 0.01).
FEV1, BMI pc, hospitalisation and PA infection were
investigated as physical parameters of CF and their im-
pact on HRQoL was assessed.
We found moderate associations between the FEV1
and CFQ-R Physical functioning score (r = 0.42, p < 0.01)
and between the FEV1 and CFQ-R Respiratory symp-
toms score (r = 0.37, R2 = 0.17, p < 0.01) by patient-
report. The relationship between the FEV1 and the
CFQ-R Body image score was weak (r = 0.30, p < 0.05)
from the patients’ perspective. A weak correlation was
found between the FEV1 and CFQ-R Digestive symp-
toms score (r = −0.27, R2 = 0.08, p < 0.05). A moderate
correlation was measured between the FEV1 and the
CFQ-R Physical functioning score (r = 0.56, p < 0.01) by
parent-proxy report.
Two subgroups were made for patients hospitalised/
not hospitalised in the last year. Twelve (70.6%) of the
patients in the hospitalised group and 17 (47.2%) of the
patients in the non-hospitalised group had PA infections.
Only in the CFQ-R Physical functioning domain could
we measure a significant difference between the hospita-
lised (CFQ-R Physical functioning = 62.91 ± 30.16) and the
non-hospitalized (CFQ-R Physical functioning = 80.98 ±
18.01) groups by patient-report (p < 0.05). Figure 1 illus-
trates the trend for mean scores in different CFQ-R do-
mains of the subgroups by parent-proxy report. The
mean spirometry value was significantly lower in the
hospitalised group (FEV1 = 63.59% ± 24.03) than in the
non-hospitalised groups (FEV1 = 84.69% ± 21.0) (p < 0.01).
Table 2 Pearson’s correlation coefficients between CFQ-R scales and demographic variables, physician–reported outcome
and physiologic parameters
CFQ-R scales Age Gender Parents’ level
of education
Parents’ chronic
illness
Passive
smoking
SK-score BMI pc FEV1 PA Hospitalization
Physical functioning 0.08 −0.2 0.09 −0.11 −0.047 0.55** 0.18 0.42** −0.22 0.36**
Emotional functioning −0.09 −0.04 −0.11 0.02 0.04 0.20 0.06 0.09 −0.16 0.16
Social functioning 0.05 −0.09 0.28 0.23 −0.16 0.02 −0.01 −0.03 0.00 −0.01
Eating 0.28* −0.12 0.00 −0.12 −0.20 0.25 0.47** 0.21 0.07 0.18
Treatment burden −0.26* −0.12 −0.02 0.10 −0.00 0.09 0.17 0.18 0.18 0.21
Body image −0.24 0.06 0.22 0.18 −0.01 0.41** 0.34* 0.3* −0.34** 0.16
Respiratory symptoms −0.10 −0.17 0.03 −0.17 −0.24 0.43** 0.14 0.37** −0.28* 0.26
Digestive symptoms −0.07 −0.02 −0.07 0.01 −0.16 −0.13 −0.14 −0.27* 0.07 −0.12
CFQ-R = The Cystic Fibrosis Questionnaire Revised.
SK-score = Shwachman-Kulczycki score, PA = Pseudomonas aeruginosa.
BMI = Body Mass Index, FEV1 = Forced Expiratory Volume in 1 second.
*p < 0.05.
**p < 0.01.
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(SK-score = 67.35 ± 17.69), while the clinical status of the
non-hospitalised patients was good (SK score = 81.94 ±
9.20), (p < 0.001).
Data were analysed in two subgroups with patients
who had PA infection and who did not have PA infec-
tion. Thirty-three (55.9%) patients were PA-culture posi-
tive and 26 (44.1%) patients had no PA infection.
Figure 2 demonstrates that most of the patients who
did not have PA infection at the time of the study rated
their HRQoL better than those who were colonised with
PA, except in the Social functioning, Eating and Digest-
ive symptoms domains. Significant associations were ob-
served between the CFQ-R scores of the two subgroups
in the Body image (p < 0.01) and Respiratory symptomsFigure 1 Mean scores of caregivers’ Cystic Fibrosis Questionnaire-R
year (n = 26). Higher scores indicating better health-related quality ofdomains (p < 0.05) by patient-report. Generally the PA
colonisation status and SK score mainly affected the
Body image by patient-report, according to stepwise
multivariate regression analysis (r = 0.34, p < 0.01 and
r = −0.3, p < 0.05, R2 = 0.28). In the School functioning
domain, we detected significantly lower CFQ-R scores
in patients with PA, according to the parent-proxy report
(p < 0.001). Significantly weaker spirometry parameters
were found in PA-infected group (FEV1 = 70.36% ± 22.72)
than in the uninfected patients (FEV1 = 87.54% ± 21.75),
(p < 0.01). The clinical severity of CF was good in both
groups, as measured by their SK scores; however, the
SK score was significantly lower in the PA-infected
group (SK score = 73.64 ± 15.1) than in the uninfected
(SK score = 83.46 ± 9.46), (p < 0.01) group.evised per dimension according to hospitalisation in the last
life. *p ≤ 0.01.
Figure 2 Mean scores of patients’ Cystic Fibrosis Questionnaire-Revised categorised according to Pseudomonas aeruginosa infection
(n = 58). Higher scores indicating better health-related quality of life. *p = 0.009, **p = 0.035.
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Subgroups were established according to BMI pc for
children under 18 years of age (n = 44). Patients’ clinical
data and HRQoL scores according to the BMI pc are
presented in Table 3. Overall, only the Eating scale was
affected significantly by the BMI pc (r = 0.47, p < 0.001,
R2 = 0,224).
Patients with low BMI pc were several times more
likely to be hospitalised (p < 0.001) and to be diagnosed
with PA infection (p < 0.05) than their adequate-weight
counterparts (>25th BMI pc). Patients with a low BMI pc
rated their HRQoL significantly weaker in the CFQ-R
Eating, Treatment burden and Body image domains
(p < 0.01) than the adequate-weight patients. From the
parents’ perspective, only the Weight dimension had a sig-
nificantly higher impact on the HRQoL of the patients
with a low BMI pc. Significantly lower FEV1 parameters
were measured in patients with a low BMI pc (p < 0.001).
The disease severity of patients under the 25th BMI pc
was mild according to their SK scores.
Level of agreement between parents and children on
child’s QoL
Table 4 shows characteristics for the CFQ-R domains in
children, young adults and caregivers. A strong correl-
ation was found between the children’s and parents’
CFQ-R scores in the Physical functioning domain. A
moderate correlation was measured between children’s
and parents’ CFQ-R scores in the Eating, Respiratory and
Digestive symptoms domains. As reported by the parents,
the lowest mean CFQ-R score was reported in the Re-
spiratory symptoms domain and the highest was reported
in the Eating domain. According to the parent-proxyreport, the Weight and Treatment burden domains had
the lowest mean CFQ-R scores, while the Emotional func-
tioning domain had the highest mean CFQ-R score.
Discussion
Our study evaluated factors affecting HRQoL among
Hungarian children, adolescents and young adults with
CF, as assessed from both the patient and parental per-
spective. Our cross-sectional, prospective and multi-
centre study was the first HRQoL trial to study Hungarian
CF patients.
The parental educational level and presence of chronic
illness did not affect the HRQoL by child report. This
result may explain why the self-report method of meas-
uring HRQoL is important in childhood. We had pre-
dicted that the parents’ educational level, which might
influence their attitude towards chronic disease, could
influence the child’s attitude and thus their perception of
HRQoL, as measured by child-self report. However, our
results did not confirm this prediction. CF is such a
complex and severe disease, affecting several organ sys-
tems and producing serious symptoms that its effects
can be readily observed by both children and their care-
givers regardless of their educational level. We also did
not observe a negative impact of passive smoking on
children’s HRQoL, although this result was not represen-
tative because of the high degree of missing data
(23.7%). One possible explanation for this result could
be that parents who smoke did not want to admit to the
extent of their smoking habits due to the probable nega-
tive impact on their chronically ill children, making it
hard for us to obtain an accurate picture of the influence
of passive smoking in children with CF.
Table 3 Comparison of patients’ clinical parameters and health-related quality of life scores according to body mass
index
Characteristics Under 3rd BMI pc 3-25th BMI pc 25-75th BMI pc 75-97th BMI pc 95%CI for
difference
p-value
Number, (%) 11 (25) 11 (25) 16 (36.4) 6 (13.6)
Age, yr ± SD 12.18 ± 3.09 10.55 ± 2.46 11.81 ± 3.02 13.17 ± 2.79 10.89-12.65 0.32
Shwachman-Kulczycki score ± SD 55.0 ± 11.18 81.82 ± 3.37 82.19 ± 7.52 90.83 ± 9.17 71.89-81.06 0.000
Pseudomonas aeruginosa positive, n (%) 9 (81.8) 4 (36.4) 7 (43.8) 1 (16.7) 0.04
Hospitalised, n (%) 9 (81.8) 4 (50) 2 (14.3) 0 (0) 0.001
FEV1 ± SD 48.45 ± 18.02 83.27 ± 16.57 89.00 ± 12.91 105.33 ± 14.03 72.23-87.09 0.000
Health-related quality of life (CFQ-R) Patients
Physical functioning ± SD 55.18 ± 29.33 81.25 ± 11.13 80.12 ± 21.38 78.94 ± 18.81 66.56-81.12 0.02
Emotional functioning ± SD 70.08 ± 9.20 76.42 ± 12.41 79.12 ± 12.41 79.17 ± 7.28 72.69-79.67 0.19
Social limitations ± SD 68.11 ± 12.88 73.54 ± 14.85 72.47 ± 16.61 63.23 ± 13.59 65.75-74.88 0.50
Eating disturbances ± SD 68.69 ± 20.98 70.00 ± 32.31 90.97 ± 16.84 90.74 ± 10.92 73.06-87.67 0.02
Treatment burden ± SD 65.66 ± 22.47 70.00 ± 26.22 84.72 ± 12.75 81.48 ± 16.72 69.59-82.34 0.07
Body image ± SD 47.47 ± 28.15 73.33 ± 27.32 80.56 ± 22.77 87.04 ± 14.77 62.74-79.889 0.005
Respiratory symptoms ± SD 53.57 ± 21.27 74.52 ± 16.53 67.83 ± 14.50 79.76 ± 12.39 62.02-73.45 0.01
Digestive symptoms ± SD 90.00 ± 14.29 83.33 ± 22.38 81.95 ± 23.96 83.34 ± 18.26 78.04-90.75 0.80
Health-related quality of life (CFQ-R) Caregivers
Physical functioning ± SD 46.76 ± 33.12 91.20 ± 10.60 87.26 ± 14.07 67.90 ± 2.13 66.96-85.90 0.000
Emotional functioning ± SD 76.67 ± 16.33 84.07 ± 5.72 76.95 ± 18.17 71.11 ± 13.88 73.06-83.61 0.53
Vitality ± SD 66.67 ± 16.33 76.67 ± 14.25 69.99 ± 11.55 60.00 ± 6.67 64.89-74.90 0.27
Eating disturbances ± SD 64.58 ± 31.42 74.07 ± 39.18 79.17 ± 21.47 66.67 ± 0.00 62.59-83.24 0.02
Treatment burden ± SD 44.45 ± 19.70 64.19 ± 14.46 65.74 ± 18.02 70.37 ± 42.07 52.67-68.16 0.10
Body image ± SD 61.11 ± 26.56 76.54 ± 23.20 85.19 ± 19.15 68.52 ± 27.40 66.56-83.79 0.16
Weight ± SD 29.17 ± 37.53 40.74 ± 32.39 86.11 ± 17.16 100.0 ± 0.00 46.62-74.22 0.000
School performance ± SD 66.67 ± 30.86 86.42 ± 17.37 77.77 ± 23.69 85.19 ± 25.66 69.34-86.91 0.39
Health perception ± SD 50.00 ± 31.43 69.14 ± 22.07 70.37 ± 19.73 70.37 ± 16.97 56.23-73.63 0.26
Respiratory symptoms ± SD 58.13 ± 21.81 79.80 ± 18.01 80.89 ± 10.31 79.889 ± 19.14 68.01-81.45 0.03
Digestive symptoms ± SD 75.00 ± 19.47 74.69 ± 13.92 63.89 ± 15.80 70.37 ± 23.13 64.22-76.41 0.42
BMI = Body Mass Index, pc = Percentile, CI = Confidence Interval, PA = Pseudomonas aeruginosa, FEV1 = Forced Expiratory Volume in 1 second, CFQ-R = The Cystic
Fibrosis Questionnaire Revised.
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http://www.ijponline.net/content/40/1/50A moderate relationship was observed between the
disease-specific HRQoL and SK score according to pa-
tients’ and their parents’ perspective in our study popu-
lation. Previous research verified a good correlation
between the SK score and lung function [22,23]. There-
fore, the SK score might be a useful tool in countries
where CF-specific HRQoL questionnaires and spirom-
etry are not accessible in clinical practice. The SK score
can provide information not only about the clinical se-
verity of CF but can also act as an indicator of the
HRQoL of affected patients.
The moderate association between the FEV1 and the
Physical functioning domain score of HRQoL (r = 0.42,
p < 0.01) was comparable to the observations of Riekert
et al. [24], Gee et al. [10] and Quittner et al. [9,25]; all
researchers reported an r between 0.42-0.57. A recentlongitudinal study confirmed the results of previous
cross-sectional studies, showing that a decrease in lung
function predicts a corresponding decrease in the
HRQoL over time [26]. This relationship is in contrast
with the result of previous HRQoL studies in patients
with asthma, which instead showed only a weak correl-
ation between spirometry and HRQoL [7,27]. A possible
rationale might be the progressive nature of CF. Unlike
asthma where patients might live their daily life like
healthy people, the overall health status of patients with
asthma deteriorates after episodes of exacerbation, which
impacts on their HRQoL. Other investigators similarly
described a negative weak, correlation between FEV1
and the Digestive symptoms domain of CFQ-R [24,28].
According to our findings malnutrition, hospitalisation
and PA infection were the most important factors to
Table 4 Comparison of the mean CFQ-R scores of children with CF to the CFQ-R scores of their parents
CFQ-R dimensions Patients Parents r
Number Mean ± SD Minimum Maximum Number Mean ± SD Minimum Maximum
Physical functioning 58 75.79 ± 23.43 11.11 100.00 32 76.43 ± 26.27 3.70 100.00 0.77**
Emotional functioning 58 75.42 ± 14.36 40.00 100.00 32 78.33 ± 14.64 40.00 100.00 0.05
Social functioning 58 70.81 ± 15.31 33.33 100.00 - - - - -
School functioning - - - - 32 78.13 ± 24.36 22.22 100.00 -
Eating 58 83.14 ± 22.25 0.00 100.00 32 72.92 ± 28.63 0.00 100.00 0.64**
Treatment burden 58 73.95 ± 23.51 0.00 100.00 32 60.42 ± 21.48 11.11 100.00 0.18
Body image 58 68.77 ± 27.65 0.00 100.00 32 75.17 ± 23.91 33.33 100.00 0.34
Respiratory symptoms 57 67.84 ± 18.03 23.81 100.00 32 74.73 ± 18.64 19.05 100.00 0.49**
Digestive symptoms 57 82.65 ± 19.36 33.33 100.00 32 70.31 ± 16.91 33.33 100.00 0.40*
Weight - - - - 32 60.42 ± 38.28 0.00 100.00 -
CFQ-R = The Cystic Fibrosis Questionnaire Revised.
Higher CFQ-R values indicate a better quality of life. P values are derived from the two-tailed t-test.
*p < 0.05.
**p < 0.01.
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http://www.ijponline.net/content/40/1/50have a significant negative impact on the HRQoL of CF
patients (p < 0.05). Our results indicate that hospitalisa-
tion had a significant impact on the Physical functioning
domain of the disease-specific HRQoL by patient-report.
PA infection resulted both in statistically and clinically sig-
nificant higher burden in the Respiratory symptoms and
in the Body image HRQoL domains, as assessed from the
patients’ perspective. Malnutrition was associated with a
lower disease-specific HRQoL, a worse clinical status,
more frequent hospitalisation and current PA infection.
In our study a strong correlation was found between
children’s and parents’ CFQ-R scores in the Physical
functioning domain, while a moderate correlation was
detected between children’s and parents’ CFQ-R scores
in the Eating, Respiratory and Digestive symptoms do-
main (p < 0.05). Quittner et al. reported similar findings
in observable dimensions in a large, multicentre, cohort
study in the United States [25]. Previous publications
identified the opposite trend between patient- and
parent-proxy report [6,29]. In the present study, Respira-
tory symptoms were associated with lower HRQoL
scores in CF patients; this is consistent with the findings
of Szyndler et al. [30].
Although we found strong and moderate correlations
in some of the CFQ-R dimensions between parents ‘an-
swers and children’s answers, different HRQoL dimen-
sions were impacted by CF in the case of parent and
child assessments. Our study found that from patient
perspective, CF affects HRQoL mainly due to limitations
in Respiratory symptoms, while from the parental per-
spective; CF affects HRQoL due to Weight problems
and Treatment burden. Our results are consistent with
the findings of Quittner and colleagues [9,25]. School
functioning and Emotional functioning were the least
problematic, according to the caregivers’ opinion of theirchildren’s HRQoL. Although parents know their chil-
dren, they may not have insight into the child’s feelings
and thoughts, which could explain their differing per-
spectives on the factors that influence HRQoL most.
Additionally, children may not wish to discuss the true
impact of CF on their lives, to avoid distressing their
parents [6]. Consequently it is necessary to obtain infor-
mation about HRQoL from both the child and his or her
caregivers. In the present study, parents overestimated
their children’s HRQoL in most of the CFQ-R domains,
which was similar to the findings of Jozefiak et al. but in
contrast to the results of Britto et al. [8,29].
We compared our national CFQ-R scores to Quittner’s
US normative data [25]. It is important to note that the
domain scores of our CFQ-R Child and CFQ-R Teen
were combined, unlike in the US study. Therefore, we
compared only the parents’ CFQ-R scores and we could
not find any relevant differences. As for the US parents’,
the Treatment burden had the lowest score, while the
Emotional functioning had the highest score, the only
parameter for which we found a larger difference be-
tween the two populations (Hungary vs. US) was the Di-
gestive symptoms domain. One rational explanation for
this finding could be that our patients’ nutritional status
is worse than that of the US sample. This could be due
to inadequate pancreatic enzyme replacement because in
clinical practice, the level of pancreatic insufficiency is
not measured in Hungary and in practice pancreatic en-
zyme supplementation is checked only by the stool con-
sistence and defecation frequency. We believe that all
these basic differences in CF care between Eastern Europe
and Western countries do not allow for true HRQoL com-
parisons; however, our CFQ-R scores could be used as ref-
erence scores for other Eastern European countries, where
the management of CF is similar.
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http://www.ijponline.net/content/40/1/50There were some limitations to this study. The chil-
dren’s (8–12 years) CFQ-R scores were combined with
the adolescents’ and young adults’ (>14 years) scores. Be-
cause 26 patients completed the CFQ-R Teen/Adult ver-
sion and 32 patients performed the CFQ-R Child
version, we could not perform subgroup analysis given
the small number of subjects. We also lost some domain
data, as the CFQ-R Teen/Adult version had more dimen-
sions than the CFQ-R Child version. Finally, the cross-
sectional nature of this study limits the conclusions.
Conclusions
This is the first disease-specific HRQoL research on
Hungarian CF patients. Our results suggest that malnu-
trition, hospitalisation and current PA infection have a
significant and negative impact on the HRQoL of CF pa-
tients. Our study provides the first comparable HRQoL
data from Eastern Europe. Moreover, the use of disease-
specific questionnaires in the routine clinical practice
could expand the utility of health-related quality of life
measurements.
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